BioLife Solutions, Inc. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $19M | — | — | — | — |
| 2025-09-30 | $28M | ↑+31.2% | $621K | ↑+136.5% | -0.3% |
| 2025-06-30 | $25M | ↑+28.9% | $-16M | ↑+23.6% | -65.5% |
| 2025-03-31 | $24M | ↑+29.9% | $-448K | ↑+95.6% | -5.1% |
| 2024-12-31 | — | — | — | — | — |
| 2024-09-30 | $21M | ↓-9.3% | $-2M | ↑+94.2% | -2.0% |
| 2024-06-30 | $20M | ↓-32.6% | $-21M | ↓-103.1% | -6.6% |
| 2024-03-31 | $18M | ↓-51.1% | $-10M | ↑+25.5% | -17.9% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 64 quarters
margin trajectory tells the operating-leverage storyGo deeper
BLFS Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyBLFS Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics